Clinical trials: 13-valent Pneumococcal Vaccine
Asplenia, β-thalassemia Major
B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals
The purpose of this study is to determine whether one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) induces immunological memory in asplenic adults and whether previously administered immunizations with the…
- Trial name
- NCT01846923
- Testing
- PCV13
- Where
- Greece
- Volunteers
- 37 people
- Sponsor
- Aghia Sophia Children's Hospital of Athens
Acute Otitis Media, Mastoiditis
Impact of Prevnar 13 on Ear Infections in Children
Prevnar (7 valent pneumococcal conjugate vaccine [7vPnC]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar.
- Trial name
- NCT01272999
- Testing
- No intervention
- Where
- 8 sites in United States
- Volunteers
- 391 people
- Sponsor
- Pfizer
Vaccination, Immunization
Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK Infants
The National Vaccine Evaluation Consortium conducts Department of Health funded trials trials to provide information to underpin changes to the national immunisation and vaccination schedule.
- Trial name
- PINC (NCT02918708)
- Testing
- Synflorix, Prevenar13
- Where
- 2 sites in United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Public Health England
Pneumococcal Disease Prevention
A Study on the Immunization Schedule for the 13-Valent Pneumococcal Polysaccharide-Conjugate Vaccine in Healthy Infants
To compare the immunogenicity of the domestically produced PCV13 vaccine in healthy 2-month-old infants following administration via the 2+1 and 3+1 schedules, with the primary endpoint being the seroprevalence of specific IgG…
- Trial name
- NCT07591181
- Testing
- the domestically produced 13-valent Pneumococcal Polysaccharide Conjugate vaccine
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Beijing Center for Disease Control and Prevention
Diseases Caused by Streptococcus Pneumoniae Serotypes
Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)
The purpose of this study is to investigate and valuate the immunogenicity and safety of the 13-valent pneumococcal polysaccharide conjugate vaccine in 2-71 months old healthy infants and toddlers (the youngest could be 6 weeks…
- Trial name
- NCT02736240
- Testing
- 7-valent pneumococcal conjugate vaccine, 13-valent pneumococcal polysaccharide conjugate vaccine
- Volunteers
- 2,760 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
HIV Infections, Pneumococcal Infections
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 18 years of age or older who have been previously immunized with at least one…
- Trial name
- NCT00963235
- Testing
- 13-valent pneumococcal conjugate vaccine, Blood draw
- Where
- 15 sites in United States
- Volunteers
- 331 people
- Sponsor
- Pfizer
Pneumococcal Vaccines, Pneumococcal Conjugate Vaccine
A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older
The purpose of this study is to evaluate the safety, tolerability and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine compared to a single dose of 23-valent pneumococcal polysaccharide vaccine in…
- Trial name
- NCT01646398
- Testing
- 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine
- Where
- 8 sites in Japan
- Volunteers
- 764 people, healthy volunteers welcome
- Sponsor
- Pfizer
Streptococcal Pneumonia, HIV/AIDS
Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults
HIV-infected patients are 30- to 100-fold more susceptible to invasive pneumococcal diseases. Pneumococcal vaccination is the best way to decrease the large pneumococcal disease burden, but the optimal timing of vaccination is…
- Trial name
- NCT03838497
- Testing
- Prevenar13
- Volunteers
- 70 people
- Sponsor
- Korea University Guro Hospital
Streptococcus Pneumoniae Infection
Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants
This study is a phase III clinical trial to evaluate the immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (multivalent conjugate) in infants aged 2 months (at least 6 weeks) and 3 months.
- Trial name
- NCT05759520
- Testing
- 13-valent pneumococcal conjugate vaccine (multivalent conjugate), Prevenar 13
- Where
- 5 sites in China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Fosun Adgenvax Biopharmaceutical Co.,Ltd.
Vaccines, Pneumococcal
Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal vaccine (13vPnC) compare to the 7-valent pneumococcal vaccine (7vPnC) and to compare the immune response to…
- Trial name
- NCT00373958
- Testing
- 13 valent pneumococcal conjugate vaccine, 7vPnc pneumococcal conjugate vaccine
- Where
- 37 sites in United States
- Volunteers
- 666 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccines, Pneumococcal
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations…
- Trial name
- NCT00366899
- Testing
- 13-valent pneumococcal conjugate vaccine, 7 valent pneumococcal conjugate vaccine
- Where
- 13 sites in Italy
- Volunteers
- 605 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Vaccine
Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate vaccine (7vPnC) when given concomitantly…
- Trial name
- NCT00689351
- Testing
- 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine
- Where
- 6 sites in South Korea
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Infections
Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants
This is a Phase 2, randomized, active-controlled, open-label study with a 3-arm parallel design. Healthy 2-month old infants (42 to 98 days of age) with no history of pneumococcal vaccination will be randomized in a 1:1:1 ratio…
- Trial name
- NCT03550313
- Testing
- Multivalent, Prevnar 13
- Where
- 48 sites in United States
- Volunteers
- 565 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections, Streptococcal Infections
A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
This is a Phase 3 randomized, observation-blinded, active-controlled, parallel-group clinical trial designed to evaluate the immunogenicity, safety, and functional antibody response of the experimental vaccine versus the control…
- Conditions
- Pneumococcal Infections, Streptococcal Infections, Bacterial Infections
- Trial name
- NCT07017777
- Testing
- PCV13i, Prevnar 13
- Where
- 3 sites in Thailand
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Vaccines, Pneumococcal Conjugate Vaccine
Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate vaccine (7vPnC) when given concomitantly…
- Trial name
- NCT00688870
- Testing
- 13-valent pneumococcal conjugate vaccine (13vPnC), 7-valent pneumococcal conjugate vaccine (7vPnC)
- Where
- 2 sites in Taiwan
- Volunteers
- 168 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Disease
A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India
The purpose of this study is to describe the safety of the study vaccine (called 13vPnC) in people who are 18-49 years of age in India.
- Trial name
- NCT05329259
- Testing
- 13-valent pneumococcal conjugate vaccine
- Where
- 5 sites in India
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
Subjects will be randomly assigned to 1 of 3 groups to receive the following vaccines: Group 1: 13-valent pneumococcal conjugate vaccine (13vPnC) and diphtheria, tetanus, and acellular pertussis vaccine (DTaP), Group 2: 7-valent…
- Trial name
- NCT01200368
- Testing
- 13-valent pneumococcal conjugate vaccine (13vPnC), diphtheria, tetanus, and acellular pertussis vaccine (DTaP), 7-valent pneumococcal conjugate vaccine (7vPnC)
- Where
- 32 sites in Japan
- Volunteers
- 551 people
- Sponsor
- Pfizer
Pneumococcal Infectious Diseases
A Lot-to-Lot Consistency Clinical Trial of PCV13
A Phase IIIb clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 to 5 years.
- Trial name
- NCT07832500
- Testing
- Sinovac PCV13 lot 1, Sinovac PCV13 lot 2, Sinovac PCV13 lot 3
- Where
- China
- Volunteers
- 1,125 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Infections
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
This study will assess the safety, tolerability and immune response of 13-valent pneumococcal conjugate vaccine (13vPnC) compared with 23-valent Pneumococcal Polysaccharide Vaccine (23vPS).
- Trial name
- NCT00427895
- Testing
- 13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
- Where
- 26 sites in United States
- Volunteers
- 2,141 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Streptococcal, Streptococcus Pneumoniae Vaccines
Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™
The primary aim of this study is to assess the reactogenicity of Synflorix vaccine and Prevenar 13 vaccine after primary vaccination at 2 and 4 months of age with either Synflorix or Prevenar 13 vaccine or Prevenar 13 and…
- Trial name
- NCT01641133
- Testing
- Synflorix (3-Dose), Synflorix (2-Dose), Synflorix (Single Dose)
- Where
- 3 sites in Mexico
- Volunteers
- 457 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline